Skip to main content
Clinical Trials/NCT01402336
NCT01402336
Completed
Phase 3

'A Multicentre, Prospective Randomized Study to Assess the Effect When GnRH Antagonist is Started Either on Stimulation Day 1 and Day 6 vs. Conventional GnRH Agonist Long Protocol in Patients With Polycystic Ovary Syndrome Undergoing IVF-ET

Seoul National University Hospital1 site in 1 country43 target enrollmentJune 2011

Overview

Phase
Phase 3
Intervention
GnRH antagonist (Cetrorelix)
Conditions
Infertility
Sponsor
Seoul National University Hospital
Enrollment
43
Locations
1
Primary Endpoint
number of oocyte retrieved
Status
Completed
Last Updated
8 years ago

Overview

Brief Summary

GnRH (Gonadotropin-releasing hormone) antagonists in IVF (in vitro fertilization) has been accomplished by several randomized controlled trials compared with conventional GnRH agonist long protocol in polycystic ovary syndrome (PCOS) patients. Moreover, there are debating issues that refer to the timing of GnRH antagonist initiation. The purpose of this study is to investigate the laboratory and clinical priority during ovarian stimulation for IVF in patients with PCOS treated with three different protocols.

Detailed Description

GnRH Antagonist is Started on Stimulation Day 1 GnRH Antagonist is Started on Stimulation Day 6 Conventional GnRH Agonist Long Protocol

Registry
clinicaltrials.gov
Start Date
June 2011
End Date
December 31, 2016
Last Updated
8 years ago
Study Type
Interventional
Study Design
Parallel
Sex
Female

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Young Min Choi

Young Min Choi

Seoul National University Hospital

Eligibility Criteria

Inclusion Criteria

  • PCOS patients (diagnosed as 2003 ASRM(The American Society for Reproductive Medicine)/ESHRE(The European Society of Human Reproduction and Embryology) consensus meeting guideline)
  • age 20-40 years
  • patients who have normal uterus
  • Korean ethnicity

Exclusion Criteria

  • patients who have abnormal thyroid function
  • patients who have abnormal prolactin test
  • patients who have diabetes, or Cushing's syndrome, or congenital adrenal hyperplasia, or androgen-producing tumor.
  • Patients who reject informed consent
  • patients who have experience of adverse events for GnRH agonist, antagonist, recombinant FSH(follicle-stimulating hormone).

Arms & Interventions

GnRH antagonist, SD #1 starting group

Start GnRH antagonist from stimulation day 1 during ovulation induction cycles

Intervention: GnRH antagonist (Cetrorelix)

GnRH antagonist, SD #6 starting group

Start GnRH antagonist from stimulation day 6 during ovulation induction cycles

Intervention: GnRH antagonist (Cetrorelix)

Conventional GnRH agonist long group

Conventional GnRH agonist long protocol

Intervention: Conventional GnRH agonist (Triptorelin)

Outcomes

Primary Outcomes

number of oocyte retrieved

Time Frame: ovum pick up day, At the point of ovum pick-up, we can count how many oocyte was retrieved. So, almost just after ovum pick-up, outcome measure will be possible.

Secondary Outcomes

  • pregnancy rate(after confirming fetal heart beat via transvaginal ultrasound. Usually 2~4 weeks after ovum pick-up day.)

Study Sites (1)

Loading locations...

Similar Trials